(SUPN) 2xFDA approvals within 5 months (LOW FLOAT 4.9 M)
This unkown low float monster awaiting 2 FDA approvals within 5 months for their Blockbusters .
Major Partnerships which means huge upfront payments coming before FDA DECISION .
First FDA approval in July will push this low float monster into double digits easily .
Get in now before the people discover this unknown Goldmine . GLTA
Supernus Pharma (SUPN)
Market Cap : $ 143 M Cash : $ 50 M Price : $5.90
VERY LOW FLOAT : 4.9 M SHRS
We use our proprietary technologies to enhance the therapeutic benefits of approved antiepileptic drugs, or AEDs, through advanced extended release formulations. Our two epilepsy product candidates are SPN-538 (extended release topiramate), for which we submitted a new drug application, or NDA, that was accepted for filing by the U.S. Food and Drug Administration, or the FDA, in November 2011, and SPN-804 (extended release oxcarbazepine) for which we submitted an NDA that was accepted for filing by the FDA in February 2012. The Prescription Drug User Fee Act, or PDUFA, date for SPN-538 is in July 2012. The PDUFA date for SPN-804 is in October 2012.